For the quarter ending 2026-03-31, CRVO had -$293,718 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -7,964,158 | -8,087,290 | -7,726,639 | -11,152,438 |
| Accretion of discount on marketable securities, net | 70,104 | 146,058 | 221,525 | 486,494 |
| Stock-based compensation expense | 349,196 | 298,735 | 291,717 | 858,182 |
| Prepaid expenses and other assets | 428,336 | -418,967 | -278,355 | 58,967 |
| Deferred grant revenue | - | - | - | 0 |
| Deferred offering costs | - | 41,250 | 105,977 | 163,354 |
| Accounts payable | 765,364 | 94,899 | -434,813 | 272,592 |
| Accrued expenses and other current liabilities | -1,097,293 | -48,096 | 454,084 | 428,169 |
| Grant receivable | -426,993 | -934,394 | -999,588 | 106,744 |
| Net cash used in operating activities | -8,018,338 | -6,575,699 | -6,465,210 | -10,409,054 |
| Purchase of marketable securities | 989,180 | 4,626,232 | 3,918,103 | 16,858,416 |
| Maturities of marketable securities | 8,700,000 | 10,000,000 | 11,500,000 | 22,000,000 |
| Net cash provided by investing activities | 7,710,820 | 5,373,768 | 7,581,897 | 5,141,584 |
| Proceeds from sale of common stock, prefunded warrants and common stock warrants | - | 0 | 0 | 0 |
| Sale of common stock under at-the-market sales agreement, net of issuance costs | - | 0 | 0 | 4,588,687 |
| Proceeds from the exercise of stock options | 13,800 | - | - | - |
| Net cash provided by financing activities | 13,800 | 0 | 0 | 4,588,687 |
| Net (decrease) increase in cash and cash equivalents | -293,718 | -1,201,931 | 1,116,687 | -678,783 |
| Cash and cash equivalents at beginning of period | 8,235,469 | 9,437,400 | 8,999,496 | - |
| Cash and cash equivalents at end of period | 7,941,751 | 8,235,469 | 9,437,400 | - |
CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO)